Genalyte Signs on European Distributors as Maverick System Gains CE Mark
News Jul 25, 2013
Genalyte, Inc. has announced that its Maverick™ Detection System that simultaneously analyzes multiple antibodies and other proteins from a single small sample is now CE marked in Europe for research use.
The company also reported its first European distribution agreements for the Maverick Detection System, signing on specialty distributors Mokascience in France, Bucher Biotec in Switzerland and KRD Molecular Technologies in the Czech Republic, Slovakia and Hungary.
Genalyte’s Maverick Detection System uses a silicon chip containing arrays of photonic ring sensors that simultaneously analyze multiple antibodies and other proteins from a single small sample.
The one-step workflow of the Maverick multiplex system can deliver accurate results in as little as 15 minutes from small volume samples of many types.
The Maverick platform has a large dynamic range and excellent sensitivity with outstanding reproducibility.
“The Maverick System and our growing family of multiplex assays have generated a great deal of interest in Europe, so this CE mark designation and the appointment of our first European distributors are especially timely,” said Martin Gleeson, PhD, Chief Scientific Officer of Genalyte.
Gleeson continued, “We plan to launch several new multiplex assays in the coming months and also expect to announce additional distributor agreements as we build a distribution network to reach pharmaceutical, biotechnology and academic researchers around the globe.”
The Maverick Detection System and its ENA 4, ENA 6 and ANA 14 Assay Kits are commercially available. Assay kits for SLE, Sjogren’s syndrome and type I diabetes research are available under Genalyte’s Technology Access Program.
Additionally, Genalyte offers researchers a Custom Spotting Service that loads proteins supplied by customers, such as antibodies, peptides, biomarkers, cytokines and antigens, onto standard-format Genalyte chips that are ready to be run on the Maverick System.
Gilead Company Wins FDA Approval for CAR T Cancer Therapy for Treatment of Adult LymphomaNews
Kite’s Yescarta™ (axicabtagene ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.READ MORE
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Mechanism Behind Inflammatory Response to Cytoplasmic DNA IdentifiedNews
A team led by LMU‘s Veit Hornung has elucidated the mechanism by which human cells induce inflammation upon detection of cytoplasmic DNA. Notably, the signal network involved differs from that used in the same context in mice.READ MORE